TY  - GEN
AU  - Yordanova,Anna
AU  - Hose,Dirk
AU  - Neben,Kai
AU  - Witzens-Harig,Mathias
AU  - Gütgemann,Ines
AU  - Raab,Marc-Steffen
AU  - Moehler,Thomas
AU  - Goldschmidt,Hartmut
AU  - Schmidt-Wolf,Ingo G H
TI  - Sorafenib in patients with refractory or recurrent multiple myeloma
SN  - 1099-1069
PY  - 2014///0506
KW  - Aged
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - pharmacology
KW  - Combined Modality Therapy
KW  - Drug Eruptions
KW  - etiology
KW  - Drug Resistance, Neoplasm
KW  - Fatigue
KW  - chemically induced
KW  - Female
KW  - Hematologic Diseases
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Interferon-alpha
KW  - therapeutic use
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Neoplasm Proteins
KW  - antagonists & inhibitors
KW  - Niacinamide
KW  - Pain
KW  - Phenylurea Compounds
KW  - Prospective Studies
KW  - Protein Kinase Inhibitors
KW  - Recurrence
KW  - Remission Induction
KW  - Salvage Therapy
KW  - Sorafenib
KW  - Thalidomide
KW  - analogs & derivatives
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/hon.2043
ER  -